What question did this study set out to answer?

To identify and clinically contextualize endocrine adverse event signals linked to CAR T-cell therapies, focusing on their co-occurrence with cytokine release syndrome.

April 14, 2026Frontiers in MedicineOpen Access

Spectrum and prognosis of CAR-T-related endocrine toxicity: glucose/calcium dysregulation, pituitary axis disorders, and overlap with CRS

View Full Paper

Ask AI

Bookmark

Authors

JLJizhou Liang FHFangyuan Hu JLJ Li

Discussion

Member takes

Overview

Pharmacovigilance analysis reveals diverse endocrine toxicities and increased mortality during cytokine release syndrome in CAR T-cell recipients, highlighting the need for systemic hormone...

Key Points

To identify and clinically contextualize endocrine adverse event signals linked to CAR T-cell therapies, focusing on their co-occurrence with cytokine release syndrome.
Conducted a retrospective disproportionality analysis using FAERS database reports (2017 to Q2 2025) across six CAR T-cell products to calculate reporting odds ratios (ROR) and information components (IC).
Performed a structured literature review to corroborate pharmacovigilance signals with published clinical cases and observational cohorts.
Identified 269 endocrine adverse event reports yielding 14 significant disproportionality signals, with hyperglycemia reported most frequently and estrogen deficiency showing the strongest signal strength (ROR₀₂₅ = 14.93).
Observed adrenal insufficiency and hypothalamo-pituitary disorders predominantly with axicabtagene, alongside frequent mortality when endocrine toxicities co-occurred with cytokine release syndrome.
Confirmed clinical relevance via literature review, showing a 39% incidence of hyperglycemia associated with cytokine release syndrome and documenting autoimmune presentations including Hashimoto thyroiditis and central diabetes insipidus.

Cite This Study

Liang et al. (2026) studied this question.

synapsesocial.com/papers/6a0cea7a6237026544fc07d8 https://doi.org/10.3389/fmed.2026.1786129

View Full Paper

Ask AI

Bookmark

April 14, 2026Frontiers in MedicineOpen Access

Spectrum and prognosis of CAR-T-related endocrine toxicity: glucose/calcium dysregulation, pituitary axis disorders, and overlap with CRS

View Full Paper

Ask AI

Bookmark

Authors

JLJizhou Liang FHFangyuan Hu JLJ Li

Discussion

Member takes

Overview

Pharmacovigilance analysis reveals diverse endocrine toxicities and increased mortality during cytokine release syndrome in CAR T-cell recipients, highlighting the need for systemic hormone...

Key Points

To identify and clinically contextualize endocrine adverse event signals linked to CAR T-cell therapies, focusing on their co-occurrence with cytokine release syndrome.
Conducted a retrospective disproportionality analysis using FAERS database reports (2017 to Q2 2025) across six CAR T-cell products to calculate reporting odds ratios (ROR) and information components (IC).
Performed a structured literature review to corroborate pharmacovigilance signals with published clinical cases and observational cohorts.
Identified 269 endocrine adverse event reports yielding 14 significant disproportionality signals, with hyperglycemia reported most frequently and estrogen deficiency showing the strongest signal strength (ROR₀₂₅ = 14.93).
Observed adrenal insufficiency and hypothalamo-pituitary disorders predominantly with axicabtagene, alongside frequent mortality when endocrine toxicities co-occurred with cytokine release syndrome.
Confirmed clinical relevance via literature review, showing a 39% incidence of hyperglycemia associated with cytokine release syndrome and documenting autoimmune presentations including Hashimoto thyroiditis and central diabetes insipidus.

Cite This Study

Liang et al. (2026) studied this question.

synapsesocial.com/papers/6a0cea7a6237026544fc07d8 https://doi.org/10.3389/fmed.2026.1786129

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark